Nutrilipid 20% is indicated as a source of calories and essential fatty acids for parenteral nutrition and also as a source of essential fatty acids when a deficiency occurs when oral or enteral nutrition is not possible, insufficient, or contraindicated.
The FDA approval will help alleviate the short supply of lipid emulsion products the US has seen over the past two years.
B.Braun vice president of Pharmaceutical Marketing Rick Williamson said the company is happy that the FDA has granted approval for Nutrilipid 20%.
"Through our state-of-the-art production facility, we are committed to providing quality clinical nutrition products so that patients have access to parenteral nutrition they often critically need," Williamson said.
"B.Braun continues to expand upon its customized approach to clinical nutrition and compounding to meet the needs of patients along the entire clinical pathway."